Corcept Therapeutics Stock Plummets 19.51% Despite Positive ROSELLA Trial Results Ranking 101st in Trading Volume

On April 1, 2025, Corcept Therapeutics (CORT) experienced a significant decline, with its trading volume dropping by 52.07% to 7.10 billion, placing it at the 101st position in the day's trading volume rankings. The stock price of Corcept Therapeutics (CORT) fell by 19.51%.

Corcept Therapeutics' pivotal Phase 3 ROSELLA trial, which enrolled 381 patients with platinum-resistant ovarian cancer across multiple sites in the United States, Europe, South Korea, Brazil, Argentina, and Canada, met its primary endpoint. The trial aimed to evaluate the efficacy of relacorilant in combination with nab-paclitaxel chemotherapy. Patients who received relacorilant alongside nab-paclitaxel chemotherapy showed a 30% reduction in the risk of disease progression, highlighting the potential of relacorilant as a treatment option for patients with platinum-resistant ovarian cancer.

Corcept Therapeutics has announced that its pivotal Phase 3 ROSELLA trial met its primary endpoint, demonstrating that relacorilant plus nab-paclitaxel significantly improved progression-free survival in patients with platinum-resistant ovarian cancer. This positive outcome underscores the therapeutic potential of relacorilant and its ability to enhance the effectiveness of standard chemotherapy treatments.

The trial met its primary endpoint, showing improved progression-free survival (PFS) and overall survival (OS) without increasing side effects. This success in the ROSELLA trial is a significant milestone for Corcept Therapeutics, as it provides a new treatment option for patients with platinum-resistant ovarian cancer.